US Oncology Research Affiliated Physician to Present Innovative Oral Clinical Study at 2010 San Antonio Breast Cancer Symposium
THE WOODLANDS, Texas, Dec. 8, 2010 /PRNewswire/ — World-class investigators affiliated with US Oncology Research participated in studies that will be presented, discussed and displayed Dec. 8-12 at the 33rd Annual San Antonio Breast Cancer Symposium (SABCS), an international scientific symposium for interaction and exchange among basic scientists and clinicians in breast cancer.
Joyce O’Shaughnessy, M.D., medical director and co-chair of the Breast Cancer Research Committee, US Oncology Research, and medical oncologist with Texas Oncology-Baylor Sammons Cancer Center, will present her study findings regarding an innovative ten-year analysis focusing on high-risk early breast cancer in an oral presentation at 3:30 pm CST, Friday, Dec. 10. The study titled “First Efficacy Results of a Randomized, Open-Label, Phase III Study of Adjuvant Doxorubicin Plus Cyclophosphamide Followed by Docetaxel with or without Capecitabine in High-Risk Early Breast Cancer” provides an in-depth look at how faster growing breast cancers react to XelodaÃ‚® (capecitabine).
In addition to the above oral presentation, Dr. O’Shaughnessy and many other US Oncology Research affiliated investigators participated in the following studies that will be displayed as posters and poster discussions at the conference:
-- Poster Discussions: 7:00 am CST, Saturday, Dec. 11: A Genomic Predictor of Survival Following Taxane-Anthracycline Chemotherapy for Breast Cancer -- Symmans WF, Hatzis C, Valero V, Booser DJ, Esserman L, Martin M, Vidaurre T, Holmes F, Souchon EA, Lluch A, Cotrina J, Gomez H, Hubbard R, Ferrer-Lozano J, Dyer R, Buxton M, Gong Y, Wu Y, Ibrahim N, Andreopoulou E, Ueno NT, Hunt K, Yang W, Nazario A, DeMichele A, O'Shaughnessy J, Hortobagyi GN, Pusztai L.(1) 5:30 pm CST, Thursday, Dec. 9: Review of Capecitabine for the Treatment of Triple-Negative Early Breast Cancer -- Steger GG, Barrios C, O'Shaughnessy J, Martin M, Gnant M. -- Posters: 7:00 am CST, Saturday, Dec. 11: A Pilot Safety and Feasibility Study of Concurrent Capecitabine and External Beam Irradiation in the Adjuvant Treatment of High Risk Early Stage Breast Cancer --Garwood DP, Spangler A, DeRose PM, Li HC, Osborne C, O'Shaughnessy J, Tripathy D. 7:00 am CST, Sunday, Dec. 12: Impact of the Number of Prior Chemotherapy Regimens on Overall Survival (OS) among Subjects with Locally Recurrent or Metastatic Breast Cancer Treated with Eribulin Mesylate: Results from the Phase III EMBRACE Study --Blum JL, Twelves CJ, Akerele C, Seegobin S, Wanders J, Cortes J. 7:00 am CST, Sunday, Dec. 12: Meta-analysis of patients with triple-negative disease from three randomized trials of bevacizumab (BV) and first-line chemotherapy as treatment for metastatic breast cancer (MBC) -- J O'Shaughnessy, G Romieu, V Dieras, M Byrtek, A-A Duenne, D Miles. 5:30 pm CST, Friday, Dec. 10: Fibroblast Growth Factor Receptor 1 Amplification and Overexpression in Breast Cancer Tissue Microarrays Using Chromogenic In Situ Hybridization and Immunohistochemistry -- Nuciforo P, Burzykowski T, Lambertini C, Gardner H, Liu WH, Lee B, Barzaghi-Rinaudo P, Rheinhardt J, Barrett C, Linnartz R, Dugan M, Hackl W, Eiermann W, Pienkowski T, Crown J, Robert N, Pawlicki M, Martin M, Finn R, Lindsay M- A, Slamon D, Press M. 5:30 pm CST, Saturday, Dec. 11: Ongoing Evaluation of Capecitabine-Based Therapy in Early Breast Cancer (EBC) -- Poole C, Barrios C, O'Shaughnessy J, Martin M, Mobus V.
Stephen Jones, M.D., medical director for US Oncology Research, co-chair of the US Oncology Breast Cancer Research Committee, and physician at Texas Oncology-Dallas, participated in a TEAM (Tamoxifen Exemestane Adjuvant Multinational) study that included nearly 10,000 patients over a five-year period. Study results will be presented as the following poster discussion and two poster displays:
-- Poster Discussion: 7:00 am CST, Saturday, Dec. 11: Competing Causes of Mortality vs. Breast Cancer Mortality at 5-years among 9766 postmenopausal women with hormone receptor positive early breast cancer treated on the TEAM study of adjuvant hormonal therapy -- Stephen E. Jones, Hein Putter, Annette Hasenburg, Cornelis J.H. van de Velde, Daniel Rea, Jean-Michel Vannetzel, Robert Paridaens, Christos Markopoulos, Yasuo Hozumi, Caroline Seynaeve. -- Posters: 5:30 pm CST, Saturday, Dec. 11: Discontinuation during tamoxifen in the sequential arm of the TEAM trial of adjuvant endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer: the effect of IES results and subsequent therapy -- Cornelis J. H. van de Velde, Elysee T. M. Hille, Daniel Rea, Caroline Seynaeve, Annette Hasenburg, Jean-Michel Vannetzel, Robert Paridaens, Christos Markopoulos, Yasuo Hozumi, Dirk G. Kieback, Lina Asmar, Jan Smeets, Johan W. R. Nortier, Peyman Hadji, John M. S. Bartlett, Hein Putter, Stephen E. Jones. 5:30 pm CST, Saturday, Dec. 11: Effects of exemestane or tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial: a meta-analysis --P. Hadji, L. Asmar, J.G.H. van Nes, T. Menschik, A. Hasenburg, J. Kuck, H. Nortier, S.E. Jones, M. Ziller
Many clinical studies led by US Oncology Research Network physicians were also predominantly featured at numerous conferences held around the world, including the annual congress for the European Society for Medical Oncology (ESMO), the annual meeting for the American Society for Clinical Oncology (ASCO) and the American Society of Hematology (ASH) Annual Meeting and Exposition.
Those studies, along with more than 30 published manuscripts, featured forward looking clinical research topics that are helping advance cancer care today and discover improved therapies for the cancer care of tomorrow. For a complete list, please contact US Oncology at 281-863-1000.
About US Oncology
US Oncology, Inc. is the nation’s leading integrated oncology company. By uniting the largest community-based cancer treatment and research network in America, US Oncology expands patient access to high-quality care and advances the science of cancer care. Headquartered in The Woodlands, Texas, US Oncology is affiliated with 1,400 community-based oncologists, and works with patients, hospitals, payers, and the medical industry across all phases of the cancer research and delivery continuum. By promoting the use of innovative technology, clinical research, evidence-based medicine and shared best practices, US Oncology improves patient outcomes and offers a better patient experience. For more information, visit www.usoncology.com.
About US Oncology Research
US Oncology conducts clinical research through US Oncology Research, its wholly-owned subsidiary and the nation’s largest community-based cancer research network. US Oncology Research has experienced investigators and dedicated research nurses who specialize in Phase I through Phase IV oncology clinical trials. US Oncology Research serves more than 90 sites in 200 locations managing more than 200 active trials at any given time. The research network has enrolled nearly 47,000 patients in more than 1,100 trials since inception in 1992 and has contributed to the development of 43 cancer therapies approved by the FDA. For more information call (866) 216-5053 or visit www.usoncology.com/oncologists.
SOURCE US Oncology